lisinopril treatment determined a significant reduction in the combined endpoint of mortality and signs/symptom of left ventricular failure at six weeks: lisinopril 15.6% vs no lisinopril 17% (2p= 0.009, OR 0.90, 95%CI 0.84-0.98);
lisinopril treatment determined a significant reduction also of mortality alone at six weeks: lisinopril 6.3% vs no lisinopril 7.1%, 11% relative reduction (2p=0.03, OR 0.88, 95%CI: 0.79-0.99)
six-week mortality was 6.5% among patients treated with nitrates and 6.9% among patients not receiving nitrates (non significant difference, 2p=0.28, OR 0.94, 95%CI: 0.84-1.05); no significant difference emerged between the two groups also with respect to the combined endpoint: nitrates 15.9% vs no nitrates 16.7% (2p=0.12, OR 0.94, 95%CI: 0.87-1.02);
six months after the AMI, the combined endpoint is still significantly reduced among patients treated with lisinopril (lisinopril 18.1% vs no lisinopril 19.3%, 2p=0.03, OR 0.92, 95%CI: 0.86-0.99), while among those treated with nitrates it appears substantially equivalent to that of controls (nitrates 18.4% vs no nitraties18.9%, 2p=0.39, OR 0.97, 95%CI: 0.90-1.04).
